Operating Segments (Tables)

6 Months Ended

Jun. 30, 2023

Operating Segments

Schedule of operating segments

	Three Months Ended
	June 30,
	2023		2022
Revenues
Specialized BioTherapeutics	$	68,505	$	—
Public Health Solutions		138,424		228,640
Total	$	206,929	$	228,640
Income (loss) from Operations
Specialized BioTherapeutics	$	(611,300)	$	(2,000,350)
Public Health Solutions		(2,247)		(1,002)
Corporate		(1,016,777)		(1,393,944)
Total	$	(1,630,324)	$	(3,395,296)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	954	$	2,783
Public Health Solutions		159		463
Corporate		477		5,266
Total	$	1,590	$	8,512
Other (Expense) Income, Net
Specialized BioTherapeutics	$	9,931	$	68,509
Corporate		8,369		(214,908)
Total	$	18,300	$	(146,399)
Share-Based Compensation
Specialized BioTherapeutics	$	27,427	$	28,343
Public Health Solutions		994		1,054
Corporate		61,621		42,273
Total	$	90,042	$	71,670

	Six Months Ended
	June 30,
	2023		2022
Revenues
Specialized BioTherapeutics	$	223,870	$	—
Public Health Solutions		240,237		416,703
Total	$	464,107	$	416,703
Income (loss) from Operations
Specialized BioTherapeutics	$	(1,521,677)	$	(3,540,078)
Public Health Solutions		(1,820)		(121,623)
Corporate		(2,257,516)		(3,925,981)
Total	$	(3,781,013)	$	(7,587,682)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	2,025	$	5,397
Public Health Solutions		337		899
Corporate		1,013		10,448
Total	$	3,375	$	16,744
Other (Expense) Income, Net
Specialized BioTherapeutics	$	16,013	$	123,588
Corporate		(54,330)		(426,622)
Total	$	(38,317)	$	(303,034)
Share-Based Compensation
Specialized BioTherapeutics	$	54,854	$	56,847
Public Health Solutions		1,988		2,108
Corporate		106,834		90,986
Total	$	163,676	$	149,941

	As of		As of
	June 30,		December 31,
	2023		2022
Identifiable Assets
Specialized BioTherapeutics	$	79,830	$	103,742
Public Health Solutions		118,791		121,290
Corporate		13,627,632		14,054,685
Total	$	13,826,253	$	14,279,717